News

Roche COVID-19 (Coronavirus) Updates

 

 

Roche's diagnostic response to COVID-19

alt

Real-time RT-PCR test

Detecting SARS-CoV-2 in currently infected patients with high sensitivity

The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.

This test can be run on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems under Emergency Use Authorization. 

cobas® SARS-CoV-2 Test

alt

Antibody test

Detecting a patient’s immune response to SARS CoV-2 with high specificity

Elecsys® Anti‑SARS‑CoV‑2 is an immunoassay intended for qualitative detection of antibodies to SARS‑CoV‑2 in human serum and plasma (K2‑EDTA, K3‑EDTA, Li‑heparin). The test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.

Elecsys® Anti-SARS-CoV-2 Test

alt

IL-6 test

Detecting SARS-CoV-2 infection-triggered hyperinflammation to determine the risk of intubation

Elecsys® IL-6 immunoassay is an in vitro diagnostic test for the quantitative determination of IL 6 (interleukin 6) in human serum or plasma. This assay is used to assist in identifying severe inflammatory response in patients with confirmed COVID 19 illness to aid in determining the risk of intubation with mechanical ventilation, in conjunction with clinical findings and the results of other laboratory testing.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.

Elecsys® IL-6